AnaptysBio Inc
Stock Watch
Stock Watch will tell you what changes at AnaptysBio Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 33.10 $ to 70.20 $ · Last price: 48.30 $ (As of: October 30, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 10/30/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| AnaptysBio Inc ANAB | 1.4 | – | 22.3 | 105.0 | -135.5 | 157.0 | 102.0 |
| Vertex Pharmaceuticals Inc VRTX | 141.4 | 33.3 | 25.7 | 55.0 | 38.1 | 9.6 | 33.1 |
| Regeneron Pharmaceuticals Inc REGN | 96.4 | 23.4 | 13.1 | 44.5 | 20.7 | 1.0 | 42.6 |
| Moderna Inc MRNA | 88.0 | – | 4.6 | -66.0 | -131.1 | -39.2 | 687.9 |
| argenx NV ARGX | 55.5 | 34.1 | 26.2 | 59.8 | 32.0 | 89.6 | 8.8 |
| BeiGene, Ltd. ONC | 41.9 | 66.1 | 33.8 | 88.9 | 19.1 | 40.2 | 18.0 |
| Revolution Medicines Inc RVMD | 39.8 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 225.0 |
| Royalty Pharma Plc RPRX | 37.0 | 36.4 | 20.8 | 95.8 | 100.3 | 5.1 | 85.4 |
| Genmab AS GMAB | 35.6 | 44.9 | 24.7 | 93.0 | 35.2 | -82.7 | 99.0 |
| Median of companies shown | 41.9 | 35.2 | 22.3 | 59.8 | 20.7 | 5.1 | 85.4 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 17 | -3 | -4 | -1.62 | -9 | 39 | 62 |
| 2017 | 10 | -29 | -30 | -1.52 | -19 | 308 | 329 |
| 2018 | 5 | -67 | -62 | -2.50 | -49 | 486 | 509 |
| 2019 | 8 | -107 | -97 | -3.60 | -70 | 405 | 435 |
| 2020 | 75 | -24 | -20 | -0.73 | -14 | 397 | 417 |
| 2021 | 63 | -57 | -58 | -2.11 | -46 | 356 | 643 |
| 2022 | 10 | -115 | -129 | -4.57 | -74 | 262 | 610 |
| 2023 | 17 | -164 | -164 | -6.08 | -121 | 88 | 452 |
| 2024 | 91 | -115 | -145 | -5.12 | -135 | 71 | 484 |
| 2025 | 235 | 48 | -13 | -0.42 | 20 | 37 | 364 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.72 | – | 43 | 378.80 | -50.50 | -67 | -67 |
| 2025: Q1 | -1.28 | – | 28 | 286.80 | -141.60 | -11 | -11 |
| 2025: Q2 | -1.34 | – | 22 | 102.90 | -173.50 | -40 | -40 |
| 2025: Q3 | 0.52 | – | 76 | 154.30 | 19.80 | -27 | -27 |
| 2025: Q4 | 1.58 | – | 108 | 151.10 | 45.80 | 98 | 98 |
| 2026: Q1 | -1.84 | – | 26 | -8.00 | -206.90 | -26 | -26 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 12 of our scanner strategies — each hit links to the scanner.
Growth
Quality & Balance Sheet
Momentum & Trend
- 21-EMA Trend
- Above the 50- & 200-SMA
- Gary Antonacci: Dual Momentum (Stock Adaptation)
- High ADR (≥5%)
- Mark Minervini: Trend Criteria — 1 Month
- RS Leader (≥90)
- Richard Moglen: Top Performers 3/6 Month
- Stan Weinstein: Stage 2
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4.20 | 2.49 – 7.06 | 101 | 1,012.5% | 4 |
| 12/31/2027 | 4.54 | 2.42 – 8.77 | 171 | 8.1% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Instead of guessing what the stock is worth, we turn the question around: what free cash flow growth has to happen for today’s market value to add up? The assumptions behind it can be moved.
Today’s market value implies roughly 26.6% growth in free cash flow per year over ten years (assumptions: discount rate 10.0%, terminal growth 2.5%).
| Free cash flow (last twelve months) | $18.1M |
|---|---|
| Market cap | $1.43B |
| Free cash flow in year ten | $191.2M |
| Terminal value as a share of market value | 70.4% |
It shows which assumption is built into today’s price, not whether that assumption will hold. Every assumption can be changed with the sliders; the figures move with them.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 183.5%
- More than 10% revenue growth is expected for the coming year 39.7%
- Share count grows by less than 3% a year 3.6%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 165.4%
- Gross margin at 40% or higher and without meaningful erosion 99.0%
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 298 m net cash
- Operating cash flow covers the profits of the last three years 86 m
- Return on capital at 15% or higher, or up versus two years ago 14.7%
- Insiders hold at least 10% or are net buyers 5.8%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
3/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 34.1%
- Exp. sales growth 3Y > 5% -14.5%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% -14.5%
- Net debt < 4x EBIT -6.2x
- EBIT positive, 10Y straight 1
- Max. EBIT decline < 50% 0.0%
- Return on equity > 15% -35.6%
- ROCE > 15% 14.7%
- Expected return > 10% -13.4%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Renton Hollings | Director | Sell | 5,000 | 49.87 | 249,372 |
| Oct 1, 2026 | Renton Hollings | Director | Other | 5,000 | 18.03 | 90,150 |
| Sep 15, 2026 | Orwin John A | Director | Other | 1,300 | 0.00 | – |
The company
About the Company
AnaptysBio, Inc., ein Biotechnologieunternehmen im klinischen Stadium, konzentriert sich auf die Bereitstellung immunologischer Therapeutika für Autoimmun- und entzündliche Erkrankungen in den USA.
- CEO Insider Trades (12 Mo.)
- selling own stock
- Employees
- 104
- Headquarters
- San Diego, CA
- Address
- 10770 Wateridge Circle, 92121 San Diego, United States
- Phone
- 858 362 6295
- Website
- anaptysbio.com
- IPO Date
- 01/26/2017
- ISIN
- US0327241065
- Stock Split
- 15:10 on 04/20/2026
Management
| Name | Title | Birth Year |
|---|---|---|
| Daniel R. Faga | President, CEO & Director | 1980 |
| Christopher M. Murphy | Chief Financial Officer | 1984 |
| Beth Mueller | Senior Vice President of Human Resources | – |
| Benjamin Stone | Chief Business Officer | 1991 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.